If You Invested in Bio-Path Hldgs Inc (BPTH)

Bio-Path Holdings, Inc. (BPTH) is a clinical-stage biotechnology company that focuses on developing targeted nucleic acid drugs for cancer and obesity using its proprietary DNAbilize® technology. According to company disclosures, DNAbilize® is a liposomal antisense RNA interference (RNAi) nanoparticle platform designed to deliver antisense oligonucleotides via simple intravenous infusion. Bio-Path has described itself as a biotechnology company working to build a portfolio of RNAi nanoparticle drugs for blood cancers, solid tumors, obesity and related metabolic diseases.

Business model and DNAbilize® platform

Bio-Path states that its business model centers on generating new drug candidates from its DNAbilize® platform and then licensing them for final development and commercialization with partners that have the expertise and scale to bring products to market. The company highlights DNAbilize® as a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered through intravenous infusion. Public communications emphasize the platform’s use of liposomal delivery and antisense technology to target specific proteins implicated in disease.

Clinical-stage pipeline

Bio-Path’s lead product candidate is prexigebersen (BP1001), which targets the Grb2 protein. Company updates describe prexigebersen as being in a Phase 2 study for blood cancers, including acute myeloid leukemia (AML). The Phase 2 AML trial is described as having three cohorts, including untreated AML patients, relapsed or refractory AML patients, and venetoclax-resistant or intolerant relapsed/refractory AML patients. In this study, prexigebersen is combined with decitabine and venetoclax in some cohorts, and with decitabine alone in another cohort. Bio-Path has reported cases of extended treatment durability and complete remission in elderly AML patients in this program.

BP1001-A is a drug product modification of prexigebersen that incorporates the same drug substance with a slightly modified formulation intended to enhance nanoparticle properties. It is in a Phase 1/1b clinical trial for advanced or recurrent solid tumors, including gynecologic cancers such as ovarian and uterine, as well as pancreatic and breast cancer. Company communications note that BP1001-A is being evaluated as a monotherapy in dose-escalation cohorts, with plans to assess it in combination with other agents such as paclitaxel and gemcitabine in later stages of the trial. Bio-Path has reported a solid tumor patient in the higher-dose cohort who experienced tumor reduction and continued stable disease after multiple treatment cycles.

Obesity and Type 2 diabetes research

In addition to oncology, Bio-Path is evaluating BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. Company press releases describe preclinical studies in muscle and liver cell models, where BP1001-A downregulated Grb2 expression, increased insulin sensitivity, and helped restore insulin signaling in the presence of fatty acids such as palmitic acid. The company has reported multiple preclinical milestones, including data suggesting that BP1001-A rescues decreases in AKT activity in liver cells and prevents cells from becoming insulin resistant. Bio-Path has stated that these findings support BP1001-A’s potential as a therapeutic option for obese patients with Type 2 diabetes and has discussed plans to complete preclinical testing and file an Investigational New Drug (IND) application.

BP1002 and AML focus

BP1002 is described by Bio-Path as its second product candidate. It targets the Bcl-2 protein, which the company notes is responsible for driving cell survival in a substantial portion of cancers. BP1002 is being evaluated in a Phase 1/1b clinical trial for relapsed or refractory AML, including venetoclax-resistant patients. Company updates explain that venetoclax is a Bcl-2 inhibitor at the protein level and that resistance can develop over time. BP1002 instead targets Bcl-2 at the mRNA level, which Bio-Path suggests may help address some mechanisms of resistance. The ongoing trial has advanced through multiple dose cohorts, and the company has reported a meaningful patient response with stable disease and a reduction in blast count after one treatment cycle in a higher-dose cohort.

BP1003 and STAT3 program

BP1003 is described as a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3. The company has communicated that it is preparing or expects to file an IND application for BP1003. Public statements also reference patent activity around P-ethoxy nucleic acids for STAT3 inhibition and for liposomal formulations, which relate to the company’s STAT3 program and DNAbilize® platform.

Intellectual property and patent portfolio

Bio-Path has highlighted an expanding global intellectual property portfolio designed to protect its DNAbilize® platform and RNAi nanoparticle drug candidates. Company disclosures mention composition of matter and methods-of-use patents covering DNAbilize® technology, which are solely owned by Bio-Path. The company reports multiple issued patents in the United States and numerous foreign patents across several countries, along with additional pending and allowed applications. These patents are described as supporting the company’s ability to apply its core technology to new protein targets and obtain new patent terms.

Corporate and trading status

Bio-Path Holdings, Inc. is incorporated in Delaware and has been listed under the symbol BPTH. A Form 25 filed with the U.S. Securities and Exchange Commission indicates that the Nasdaq Stock Market LLC removed Bio-Path’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. Subsequent company press releases and SEC filings refer to trading on the OTCQB or OTC Markets, indicating that Bio-Path’s shares have traded on over-the-counter markets following the Nasdaq delisting.

In an 8-K filing, the company disclosed that it instituted a company-wide operational pause to conserve capital, furloughed most employees, and paused most operations while seeking financing or additional capital. The filing notes that if Bio-Path is unable to secure financing or raise additional capital, it may need to delay, reduce, or eliminate drug development programs, license or dispose of technology or product rights earlier than planned or on less favorable terms, or potentially liquidate and dissolve the company. Another 8-K describes management and board changes, including resignations of senior executives and directors and the appointment of new leadership.

Risk profile and company stage

Based on its public statements, Bio-Path is a clinical-stage biotechnology company without approved commercial products. Its programs are in various stages of clinical and preclinical development, and the company has disclosed ongoing operating losses and a need for external financing. Regulatory filings explicitly state that there is substantial doubt about the company’s ability to continue as a going concern if it cannot raise additional capital. Investors considering BPTH stock therefore face the risks typical of early-stage biotechnology companies, including clinical, regulatory, financing, and operational uncertainties.

Summary

In summary, Bio-Path Holdings, Inc. is focused on developing RNAi nanoparticle drugs using its DNAbilize® liposomal antisense platform. Its pipeline includes prexigebersen (BP1001) for blood cancers such as AML, BP1001-A for solid tumors and obesity-related metabolic diseases in Type 2 diabetes, BP1002 targeting Bcl-2 in blood cancers and solid tumors, and BP1003 targeting STAT3. The company emphasizes its patent portfolio and platform-based approach to generating new candidates, while SEC filings and press releases underscore its dependence on additional financing and the operational impact of capital constraints.